AU2006330660A1 - RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) - Google Patents
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) Download PDFInfo
- Publication number
- AU2006330660A1 AU2006330660A1 AU2006330660A AU2006330660A AU2006330660A1 AU 2006330660 A1 AU2006330660 A1 AU 2006330660A1 AU 2006330660 A AU2006330660 A AU 2006330660A AU 2006330660 A AU2006330660 A AU 2006330660A AU 2006330660 A1 AU2006330660 A1 AU 2006330660A1
- Authority
- AU
- Australia
- Prior art keywords
- nucleotides
- sina
- strand
- molecule
- sina molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/311,826 US20060211642A1 (en) | 2001-05-18 | 2005-12-19 | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| US11/311,826 | 2005-12-19 | ||
| US11/510,872 | 2006-08-25 | ||
| US11/510,872 US20080207542A1 (en) | 2002-03-26 | 2006-08-25 | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| PCT/US2006/062252 WO2007076328A2 (fr) | 2005-12-19 | 2006-12-18 | INHIBITION A MEDIATION PAR INTERFERENCE ARN DE L'EXPRESSION DU GENE DU VIRUS DE L'HEPATITE C (VHC) AU MOYEN D'ACIDE NUCLEIQUE INTERFERENT COURT (siNA) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006330660A1 true AU2006330660A1 (en) | 2007-07-05 |
Family
ID=38121890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006330660A Abandoned AU2006330660A1 (en) | 2005-12-19 | 2006-12-18 | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080207542A1 (fr) |
| EP (1) | EP1987145A2 (fr) |
| KR (1) | KR20080079329A (fr) |
| AU (1) | AU2006330660A1 (fr) |
| CA (1) | CA2633684A1 (fr) |
| NO (1) | NO20083208L (fr) |
| WO (1) | WO2007076328A2 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514099B2 (en) | 2005-02-14 | 2009-04-07 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| US7935812B2 (en) | 2002-02-20 | 2011-05-03 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
| US8138161B2 (en) | 2004-10-01 | 2012-03-20 | Novartis Vaccines And Diagnostics, Inc. | Modified small interfering RNA molecules and methods of use |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2007010853A1 (fr) * | 2005-07-15 | 2007-01-25 | National University Corporation Nagoya University | Procédé de commande d'un appareil d'électroporation |
| WO2009029681A2 (fr) | 2007-08-27 | 2009-03-05 | The Regents Of The University Of California | Micro-arn utilisés pour inhiber la réplication virale |
| JP2011529912A (ja) * | 2008-07-31 | 2011-12-15 | エンゾン ファーマシューティカルズ,インコーポレーテッド | 核酸送達システム用のナノ粒子組成物 |
| JPWO2010061881A1 (ja) * | 2008-11-26 | 2012-04-26 | 中外製薬株式会社 | C型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| WO2010105372A1 (fr) * | 2009-03-20 | 2010-09-23 | Protiva Biotherapeutics, Inc. | Compositions et procedes d'inactivation de l'expression du virus de l'hepatite c |
| EA026374B1 (ru) | 2009-12-23 | 2017-04-28 | Новартис Аг | Липиды, липидные композиции и способы их применения |
| CN103209987B (zh) | 2010-09-22 | 2017-06-06 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| ES2633565T3 (es) | 2010-11-12 | 2017-09-22 | The General Hospital Corporation | ARN no codificantes asociados a polycomb |
| DK2756080T3 (da) | 2011-09-14 | 2019-05-20 | Translate Bio Ma Inc | Multimeriske oligonukleotidforbindelser |
| HK1203075A1 (en) | 2011-12-22 | 2015-10-16 | 艾丽奥斯生物制药有限公司 | Substituted phosphorothioate nucleotide analogs |
| NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
| WO2013142157A1 (fr) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Combinaisons pharmaceutiques comprenant un analogue thionucléotidique |
| AU2013262649A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating smn gene family expression |
| EP2850190B1 (fr) | 2012-05-16 | 2020-07-08 | Translate Bio MA, Inc. | Compositions et méthodes pour moduler l'expression de mecp2 |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| AU2013315225B2 (en) | 2012-09-14 | 2018-11-08 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| CA2966044A1 (fr) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Procedes de modulation de la repression genique dependant d'atrx |
| US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
| WO2020181144A1 (fr) * | 2019-03-06 | 2020-09-10 | Northwestern University | Acide nucléique sphérique conjugué à un oligonucléotide de type épingle à cheveux |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087541A1 (fr) * | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Formulations a base de lipides pour transfert genique |
| WO2005078097A2 (fr) * | 2004-02-10 | 2005-08-25 | Sirna Therapeutics, Inc. | Inhibition induite par l'interference arn de l'expression genetique, a l'aide d'un acide nucleique interferant court multifonctionnel (sina multifonctionnel) |
| WO2005028650A2 (fr) * | 2003-09-16 | 2005-03-31 | Sirna Therapeutics, Inc. | Inhibition a mediation par interference arn de l'expression du gene du virus de l'hepatite c (vhc) au moyen d'acide nucleique interferent court (sina) |
-
2006
- 2006-08-25 US US11/510,872 patent/US20080207542A1/en not_active Abandoned
- 2006-12-18 CA CA002633684A patent/CA2633684A1/fr not_active Abandoned
- 2006-12-18 EP EP06846665A patent/EP1987145A2/fr not_active Withdrawn
- 2006-12-18 AU AU2006330660A patent/AU2006330660A1/en not_active Abandoned
- 2006-12-18 WO PCT/US2006/062252 patent/WO2007076328A2/fr not_active Ceased
- 2006-12-18 KR KR1020087017733A patent/KR20080079329A/ko not_active Withdrawn
-
2008
- 2008-07-18 NO NO20083208A patent/NO20083208L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20083208L (no) | 2008-09-18 |
| EP1987145A2 (fr) | 2008-11-05 |
| CA2633684A1 (fr) | 2007-07-05 |
| WO2007076328A2 (fr) | 2007-07-05 |
| WO2007076328A3 (fr) | 2008-08-14 |
| KR20080079329A (ko) | 2008-08-29 |
| US20080207542A1 (en) | 2008-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7935812B2 (en) | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) | |
| US7915400B2 (en) | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) | |
| AU2006330660A1 (en) | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) | |
| US20060211642A1 (en) | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) | |
| US20050287128A1 (en) | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) | |
| US20040209831A1 (en) | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) | |
| US20090156533A1 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| WO2007084865A2 (fr) | INHIBITION DE L’EXPRESSION DU GENE B7-H1 MEDIEE PAR UNE INTERFERENCE DE L’ARN EN UTILISANT UN ACIDE NUCLEIQUE INTERFERANT COURT (NAsi) | |
| US20070270360A1 (en) | Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid | |
| US20050209180A1 (en) | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) | |
| AU2007275365A1 (en) | RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) | |
| WO2005028650A2 (fr) | Inhibition a mediation par interference arn de l'expression du gene du virus de l'hepatite c (vhc) au moyen d'acide nucleique interferent court (sina) | |
| US7662952B2 (en) | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) | |
| US8258288B2 (en) | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) | |
| EP1891217A2 (fr) | Inhibition, mediee par l'interference d'arn, de l'expression genique du facteur 1 derive des cellules stromales (sdf-1), au moyen d'acide nucleique interferant court (sina) | |
| WO2010062817A1 (fr) | Inhibition véhiculée par arn interférence de l’expression du gène de canal sodique épithélial (enac) utilisant un acide nucléique interférant court (ansi) | |
| US20070099858A1 (en) | RNA interference mediated of inhibition of influenza virus gene expression using short interfering nucleic acid (siNA) | |
| US20090247613A1 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| US20060287267A1 (en) | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) | |
| US7928220B2 (en) | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) | |
| US20090298914A1 (en) | RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA) | |
| WO2009055445A2 (fr) | Inhibition induite par l'interférence arn de l'expression du virus syncytial respiratoire (vsr), au moyen d'un acide nucléique interférant court (sina) | |
| JP2009520039A (ja) | 低分子干渉核酸(siNA)を用いた、RNA干渉によって媒介される、C型肝炎ウイルス(HCV)遺伝子発現の阻害 | |
| US20070179104A1 (en) | RNA interference mediated inhibition of winged helix nude (WHN) gene expression using short interfering nucleic acid (siNA) | |
| EP1844147A2 (fr) | Inhibition a mediation d'interference d'arn de l'expression genique du retinoblastome (rbi) au moyen de l'acide nucleique a interference courte (sina) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |